Oncobiologics Enters First CDMO Contract

Oncobiologics  has entered into a Master Services Agreement (MSA) with Sonnet BioTherapeutics, a privately held development stage biopharmaceutical company, and has officially launched its BioSymphony Platform-based contract development and manufacturing (CDMO) business. The terms of the MSA were not disclosed, but the MSA engages Oncobiologics to provide CDMO services for up to four drug product candidates over the next three years.

"We are excited to sign our first CDMO contract to leverage our BioSymphony Platform capacity with development stage partners," said Pankaj Mohan, chairman and chief executive officer, Oncobiologics. "Our Biosymphony Platform capabilities have generated a great deal of interest and we look forward to leveraging our recently announced participation in the Bio2Source program to add additional partners for our CDMO services. We believe this CDMO business, and the associated revenue, integrated with our ongoing efforts to develop our own proprietary innovative and biosimilar product candidates, will help us to reduce costs and improve efficiency to drive stockholder value."

Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) therapeutics. The company is advancing a pipeline of innovative and biosimilar product candidates, three of which are currently in, or about to enter, clinical development. By leveraging its proprietary BioSymphony Platform, the company says it is able to produce high-quality innovative and biosimilar mAb candidates efficiently and cost-effectively.

The BioSymphony engine is particularly suitable for developing technically challenging and commercially attractive mAbs to meet the need for clinically important yet affordable drugs. The BioSymphony Platform is used for both in-house programs as well as engaging capacity to provide external CDMO services. Led by a team of biopharmaceutical experts, Oncobiologics operates from a state-of-the-art fully integrated research, development, and manufacturing facility in Cranbury, New Jersey.